Tiny study tests how liver disease changes drug processing
NCT ID NCT07049939
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how the drug bomedemstat behaves in people with mild or moderate liver impairment compared to healthy volunteers. Nine participants received a single dose, and researchers measured drug levels in the blood. The goal is to understand if liver problems require dose adjustments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bomedemstat (MK-3543)
What this could lead to
If successful, this study could help doctors decide the right dose of bomedemstat for people with liver problems.
What could go wrong
This is a very early, small study with only 9 participants, so results may not apply to everyone. The drug may still cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Orlando Clinical Research Center ( Site 0001)
Orlando, Florida, 32809, United States
-
The Texas Liver Institute ( Site 0002)
San Antonio, Texas, 78215, United States
-
University of Miami ( Site 0003)
Miami, Florida, 33136, United States